Jubilant Ingrevia Ltd. · NSE:JUBLINGREA

Jubilant Ingrevia — Investor Presentation (July 2022)

44 slides from Jubilant Ingrevia's investor presentation, Jul 4, 2022

  1. Slide 1: Intimation of Investor/Analyst Meetings

    July 4, 2022 BSE Limited National Stock Exchange of India Limited P. J. Towers Exchange Plaza Dalal Street, Bandra Kurla Complex Mumbai - 400 001 Bandra (E), Mumbai - 400 051 Dear Sirs, Sub.: Intimation of Investor/ Analyst Meetings Pursuant to the provisions of Regulation 30 of the Securities and E

  2. Slide 2: Meetings Schedule

    Meetings Schedule Date Investors Name 05-Jul-22 Abakkus Asset Managers LLP 05-Jul-22 Lucky Investment Managers 05-Jul-22 Grantham Mayo Van Otterloo & Co 05-Jul-22 Ashmore Investments 05-Jul-22 HDFC Mutual Fund 05-Jul-22 Dymon Asia 06-Jul-22 Value Quest 06-Jul-22 IDFC Mutual Fund 06-Jul-22 Aditya Bir

  3. Slide 3: Investor Presentation June 2022

    Investor Presentation June 2022

  4. Slide 4: Disclaimer

    Disclaimer Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates f

  5. Slide 5: Company Overview

    __ Company Overview

  6. Slide 6: Jubilant Bhartia Group - Snapshot

    Jubilant Bhartia Group - Snapshot Jubilant Bhartia Group founded by Shyam S Bhartia and Hari S Bhartia, leading industrialists from India Strong presence in diverse sectors like Pharmaceuticals, CDMO (Contract Research & Development Services) and Therapeutics, Specialty Chemicals, Nutraceutical Prod

  7. Slide 7: Integrated Business Model

    Integrated Business Model Jubilant Ingrevia Integrated Operations… 52% of our Pyridine & Picolines Speciality Nutrition & Health Chemical volume is used in-house for value- Chemicals Solutions Intermediates# added products in Speciality Nutrition & Pyridine & Chemicals & for Vitamin B3 Nutrition & H

  8. Slide 8: Glorious Four Decades of Growth

    Glorious Four Decades of Growth Commissioning of Our Journey 10+ years experience in 2019: Started new Acetic Anhydride plant, Bharuch SEZ, GJ (50 KTA) Phase1: Diketene 2018: Started Agro Intermediate plant (800 TPA), Bharuch SEZ Derivative Plant Vitamin B3 2022 2017: Certified for Responsible Care

  9. Slide 9: Company Snapshot

    Company Snapshot Leadership Revenue Segmentation: By Region (FY’22) Total 1400+ customers - Globally # 1 in 17 Pyridine Derivatives • Speciality Chemicals: 420 - Globally among Top 2 in (Pyridine + Beta) N.America RoW Domestic Sales • Nutrition & Health Solutions: 400 5% 10% for International • Chem

  10. Slide 10: Executive Leadership Team

    Executive Leadership Team Rajesh Srivastava Chief Executive Officer & Managing Director 35 years of industry experience Anil Khubchandani Chandan Singh Sumit Das Ashish Kumar Sinha Co-CEO & WTD Co-CEO SVP – Nutrition & VP – Animal & Human Speciality Chemicals Chemical Intermediates Health Ingredient

  11. Slide 11: Multi Location Manufacturing & Operation Excellence

    Multi Location Manufacturing & Operation Excellence Manufacturing Facilities 463 acres 310 acres 144 acres 109 acres 3.5 acres Gajraula, Uttar Pradesh, Bharuch, Gujarat, India Nira, Maharashtra, India Samlaya, Gujarat, India Ambernath, Maharashtra, India Speciality Chemicals, Chemical Intermediates

  12. Slide 12: Research Development & Technology (RDT)

    Research Development & Technology (RDT) 3 RDT centers in Noida, Gajraula and Bharuch 35 Key technology platforms developed & commercialized to global standards. Some are unique: Ammoxidation, Key Grignard etc. Highlights 92 highly qualified scientists (22 PhDs) 60+ Products in Pipeline for next 4 ye

  13. Slide 13: End Usage Applications for Pharma, Agrochemicals & Nutraceuticals

    End Usage Applications for Pharma, Agrochemicals & Nutraceuticals Therapeutic Category Our Product Category (GMP & Non-GMP) (Used in ~ 53 APIs) Pyridine, Picolines Amino Methyl Chloro/ Bromo/ Pyridines Fluoro Pyridines Antipyretic Analgesic Antifibrosis Off- Patented Amino Pyridines Hydroxy Methyl P

  14. Slide 14: Industry Overview: Presence in Large & Growing Markets

    Industry Overview: Presence in Large & Growing Markets1 Global Speciality Chemicals Global API Market CAGR 6.4% CAGR 5.8% $ 910 Bn $ 1240 Bn $ 197 Bn $ 262 Bn Speciality FY'21 FY 26 P FY'21 FY'26 P Chemicals Indian Speciality Chemicals Indian API Market CAGR 12.4% CAGR 7.9% $ 41 Bn $ 72 Bn $ 4 Bn $

  15. Slide 15: Financial Highlights: Q4 FY'22 & FY'22

    Financial Highlights: Q4 FY’22 & FY’22

  16. Slide 16: Chairmen's Message on Q4'FY22 Financial Results

    Chairmen’s Message on Q4’FY22 Financial Results Mr. Shyam S Bhartia Mr. Hari S Bhartia Chairman Co-Chairman “We are pleased to announce that we delivered record financial performance during FY’2022 despite facing severe second wave of pandemic at beginning of the year and then headwinds and volatili

  17. Slide 17: Financial Highlights: Key Financial Parameters

    Financial Highlights1 : Key Financial Parameters Highlights ₹ 1,296 Cr. ₹ 152 Cr. 11.7% ₹ 69 Cr. 5.3% ₹ 4.3 Q4’FY22 Sales EBITDA EBITDA (%) PAT PAT (%) EPS 20% YoY (25)% YoY (710) bps (28)% YoY (355) bps 28% YoY Highlights ₹ 1,078 Cr. ₹ 203 Cr. 18.8% ₹ 95 Cr. 8.8% ₹ 6.0 Q4’FY21 2 Sales EBITDA EBITDA

  18. Slide 18: Jubilant Ingrevia – Q4 FY'22 Financial Results Summary

    Jubilant Ingrevia – Q4 FY’22 Financial Results Summary Particulars 1 Q4'FY21 2 Q4'FY22 YoY (%) FINANCIAL HIGHLIGHTS Revenue Speciality Chemicals 329 444 35% • Revenue grew by 20% on YoY basis, driven by growth in Speciality Nutrition & Health Solutions 199 206 3% Chemicals and Chemical intermediate

  19. Slide 19: Jubilant Ingrevia – FY'22 Financial Results Summary

    Jubilant Ingrevia – FY’22 Financial Results Summary Particulars 1 FY212 FY22 YoY (%) FINANCIAL HIGHLIGHTS Revenue Speciality Chemicals 1,124 1,393 24% • Revenue grew by 42% on YoY basis, driven by growth across Business Nutrition & Health Solutions 630 767 22% segments. Chemical Intermediates 1,738

  20. Slide 20: Acetic Acid Price Volatility Led Stock Impact on EBITDA Margins

    Acetic Acid Price Volatility Led Stock Impact on EBITDA Margins 1 Chemical Intermediates Q1 FY'22 Q2 FY'22 Q3 FY'22 Q4 FY'22 FY'22 Revenue 673 749 722 646 2,789 Reported EBITDA 184 103 100 30 417 Reported EBITDA % 27.3% 13.8% 13.9% 4.6% 14.9% Acetic Acid price impact on Business 27 -25 30 -54 -22 No

  21. Slide 21: Debt Profile – As on 31st March, 2022

    Debt Profile – As on 31st March, 2022  Gross Debt reduction by Rs 319 Crore and Net Debt reduction by Rs 251 Crore from 31st March 2021.  Net Debt to EBITDA as on 31st March FY22 stands at 0.21 times, from the earlier level of 0.69 times as on 31st March, 2021.  Closing blended interest rate in Q

  22. Slide 22: Balance Sheet – Key Parameters/Ratios (Pro-Forma)

    Balance Sheet – Key Parameters/Ratios (Pro-Forma2) Return On Capital Employed (RoCE) Return on Equity Asset / Turnover and Return On Asset (RoA) 2.0x 2.8x 27.8% 21.9% 13.3% 20.2% 9.4% (%age) (%age) (%age) 16.4% FY'21 FY'22 FY'21 FY22 FY'21 FY22 FY'21 FY'22 FY'21 FY22 Asset / Turnover FY'21 FY22 Net

  23. Slide 23: Business Segments Overview

    BUSINESS SEGMENTS OVERVIEW

  24. Slide 24: Speciality Chemicals – Segment Snapshot

    Speciality Chemicals – Segment Snapshot Geographical Revenue Split (FY’22) 85+ Products Domestic Sales Globally among Top 2 in Globally lowest cost (Pyridines & Picolines, for International Cyanopyridines, (Pyridine+Beta); producer of Pyridine Consumption Piperidines, Globally #1 in 17 Pyridine offe

  25. Slide 25: Speciality Chemicals Segment Highlights – Q4 FY'22

    Speciality Chemicals Segment Highlights – Q4 FY’22 FINANCIAL HIGHLIGHTS Particulars1 Q4'FY212 Q4'FY22 YoY (%)  Specialty Chemicals revenue grew by 35% on YoY basis driven Revenue 329 444 35% by higher volume across product segments Reported EBITDA 69 81 17%  Share of revenue to customers having Ag

  26. Slide 26: Speciality Chemicals Segment Highlights – FY'22

    Speciality Chemicals Segment Highlights – FY’22 Particulars1 FY212 FY22 YoY (%) FINANCIAL HIGHLIGHTS Revenue 1,124 1,393 24%  Specialty Chemicals revenue grew by 24% on YoY Reported EBITDA 268 312 16% basis driven by higher volume across products and Reported EBITDA Margin (%) 23.9% 22.4% new launc

  27. Slide 27: Nutrition & Health Solutions – Segment Snapshot

    Nutrition & Health Solutions – Segment Snapshot Revenue Segmentation (FY’22) 5 Nutrition Ingredients Global top 2 in Vitamin B3 100% in-house sourcing Domestic Sales for By End use & Domestic Consumption Cosmetics & Others*, 5% 18+ branded solutions Domestic leader in of Beta Picoline (Key RM) for B

  28. Slide 28: Nutrition & Health Solutions Segment Highlights – Q4 FY'22

    Nutrition & Health Solutions Segment Highlights – Q4 FY’22 FINANCIAL HIGHLIGHTS Particulars1 2 Q4'FY21 Q4'FY22 YoY (%) Revenue 199 206 3%  Growth of Nutritional Business was driven by higher prices. Reported EBITDA 43 50 18%  Revenue share from North America increased to 19% as against Reported EB

  29. Slide 29: Nutrition & Health Solutions Segment Highlights – FY'22

    Nutrition & Health Solutions Segment Highlights – FY’22 1 Particulars FY212 FY22 YoY (%) FINANCIAL HIGHLIGHTS Revenue 630 767 22% Reported EBITDA 130 164 26%  Nutrition and Health Solutions revenue grew by 22% Reported EBITDA Margin (%) 20.7% 21.4% - on YoY basis. • Growth of Vitamin Business was d

  30. Slide 30: Chemical Intermediates – Segment Snapshot

    Chemical Intermediates – Segment Snapshot Entered Value added Region wise Revenue Segmentation Acetic Anhydride: 8 Products Globally No. 2 in derivative Propionic For Segment (FY’22) Domestic Sales for (Acetic Anhydride, Ethyl Merchant Mkt Anhydride to RoW 3% International Acetate ,Propionic Anhydri

  31. Slide 31: Chemical Intermediates Segment Highlights – Q4 FY'22

    Chemical Intermediates Segment Highlights – Q4 FY’22 FINANCIAL HIGHLIGHTS Particulars1 Q4'FY212 Q4'FY22 YoY (%) Revenue 549 646 18%  Chemical Intermediates revenue grew by 18% on YoY basis Reported EBITDA 105 30 (72%)  Chemical Intermediates revenue growth was driven by higher Reported EBITDA Marg

  32. Slide 32: Chemical Intermediates Segment Highlights – FY'22

    Chemical Intermediates Segment Highlights – FY’22 Particulars 1 FY21 2 FY22 YoY (%) FINANCIAL HIGHLIGHTS Revenue 1,738 2,789 61%  Chemical Intermediates revenue grew by 61% on YoY Reported EBITDA 236 417 77% basis Reported EBITDA Margin (%) 13.6% 14.9% • Chemical Intermediates revenue growth was Pr

  33. Slide 33: Growth Plans & Outlook

    Growth Plans & Outlook

  34. Slide 34: Growth Capex Investment Plan – Business Wise

    Growth Capex Investment Plan – Business Wise (Already Committed & to be Committed) Additional Capex to be Committed during FY’23 & FY’24~ Rs. 1250 Crores Committed till date ~ Rs. 800 Crores Estimated Cash Outflow (FY’22 Cash Outflow ~ Rs.235 Cr.) ~ (Rs.550 Cr, Rs.650 Cr. & Rs.600 Cr. respectively i

  35. Slide 35: Capacity Build-Up Plan – FY'22 to FY'25

    Capacity Build- Up Plan – FY’22 to FY’25 (over Base of FY’22) Overall Capacity Build-Up Speciality Chemicals Capacity Build-Up Capacity Expansion Plan Capacity Expansion Plan (Overall capacity increase : 40.5% & CAGR: 12.0%) (Overall capacity increase: 44.7% & CAGR: 13.1%) 30.0% 32.3% 15.6% 1.5% 7.9

  36. Slide 36: Structural Shift towards Speciality via Growth Capex Plans

    Structural Shift towards Speciality via Growth Capex Plans Speciality & Nutrition will be 65% of Revenue up from present 46% post commissioning of our announced growth capex plans Revenue in INR Crores at Base price of FY’21 Speciality, Nutrition & Others: 65% Acetyls: 35% Speciality, Nutrition & Ot

  37. Slide 37: Quality, Business Excellence, Sustainability

    BUSINESS QUALITY SUSTAINABILITY EXCELLENCE

  38. Slide 38: Jubilant Ingrevia: Global Accreditation

    Jubilant Ingrevia: Global Accreditation Select Certifications Gajraula Bharuch Nira Samlaya Ambernath Responsible Care    RC 14001:2015 ISO      9001:2015 ISO    22000:2005 ISO     14001:2015 ISO     45001:2018 FSSAI     FAMI-QS   HALAL    KOSHER   GMP State State FDA G

  39. Slide 39: Business Excellence and Digital Transformation

    Business Excellence and Digital Transformation Belt Competencies (FY’22) Digital Transformation Black Belts: 07 Green Belts: 103 Yellow Belts: 95  Our journey started in 2018 with an objective to improve Business Excellence  Operational efficiency Tools & Processes  Business & Supply chain proces

  40. Slide 40: Bring Progressive Social Change via Strategic Multi-Stakeholder Partnership

    Bring Progressive Social Change via Strategic Multi-Stakeholder Partnership Mission: To develop multi-stakeholder sustainable Aspiring to touch 1 Million Established models to bring about ‘social change’ involving the Lives through in 2007 knowledge generation & sharing, experiential lives social in

  41. Slide 41: Sustainability Journey

    Sustainability Journey 2001 2002 2003 2005 2008 2009 2010 2013 2015 2019 2021 Climate Became GRI Change Became UNGC SoFI Sustainability Sustainability Sustainability Jubilant Bhartia 1st EvoVadis Dow Jones ISO ISO 14000 14000 Sustainability Organization Mitigation Signatory and Sustainability Goals

  42. Slide 42: Our Vision, Values, Promise and Philosophy

    Our Vision, Values, Promise and Philosophy OUR PHILOSOPHY Caring Sharing Growing

  43. Slide 43: For More Information

    For More Information For Investors: Siddharth Rangnekar CDR India Pavleen Taneja Ph: +91 22 6645 1209 Ph: +91 120 436 1021 E-mail: siddharth@cdr-india.com E-mail: pavleen.taneja@jubl.com For Media: Clayton Dsouza Sudhakar Safaya Madison Public Relations Ph: +91 120 436 1034 E-mail: clayton.dsouza@ma

  44. Slide 44: Appendix I: Income Statement – Q4 & FY'22

    Appendix I: Income Statement – Q4 & FY’22 1 2 2 Particulars Q4'FY21 Q4'FY22 YoY (%) FY21 FY22 YoY (%) Total Revenue from Operations 1,078 1,296 20% 3,491 4,949 42% Speciality Chemicals 329 444 35% 1,124 1,393 24% Nutrition & Health Solutions 199 206 3% 630 767 22% Chemical Intermediates 549 646 18%

Jubilant Ingrevia — Investor Presentation (July 2022) on 6ix